Univariate and multivariable analyses of patient characteristics associated with Neisseria gonorrhoeae with a ceftriaxone MIC ≥0.015 mg/L among heterosexual men and women, 2011–2013
| Patient characteristic | Ceftriaxone MIC ≥0.015 mg/L (%) | Crude OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|---|
| Age, years | |||
| <25 (n=2664) | 160 (6.01) | 1 | 1 |
| 25–34 (n=1332) | 162 (12.2) | 2.17 (1.72 to 2.73)* | 1.56 (1.34 to 1.82)* |
| 35+ (n=630) | 136 (21.6) | 4.31 (3.34 to 5.55)* | 1.96 (1.66 to 2.31)* |
| Ethnicity | |||
| White (n=2239) | 288 (12.8) | 1 | 1 |
| Black Caribbean (n=988) | 40 (4.05) | 0.29 (0.20 to 0.41)* | 0.36 (0.28 to 0.47)* |
| Black African (n=307) | 27 (8.79) | 0.66 (0.43 to 0.99)* | 0.50 (0.35 to 0.71)* |
| Black other (n=305) | 9 (2.95) | 0.21 (0.10 to 0.41)* | 0.32 (0.20 to 0.51)* |
| Asian, including Chinese (n=308) | 44 (14.3) | 1.14 (0.81 to 1.60) | 1.21 (0.96 to 1.54) |
| Other ethnicity (n=26) | 5 (19.2) | 1.62 (0.61 to 4.35) | 0.56 (0.28 to 1.16) |
| Mixed ethnicity (n=288) | 33 (11.5) | 0.88 (0.60 to 1.30) | 0.78 (0.58 to 1.05) |
| Sexual partners in the 3 months prior to diagnosis | |||
| 0–1 (n=2135) | 193 (9.04) | 1 | |
| 2–5 (n=2140) | 220 (10.3) | 1.15 (0.94 to 1.41) | |
| 6+ (n=192) | 26 (13.5) | 1.58 (1.01 to 2.44)* | |
| Sex abroad in the 3 months prior to diagnosis | |||
| No (n=3739) | 327 (8.75) | 1 | |
| Yes (n=471) | 83 (17.6) | 2.23 (1.71 to 2.91)* | |
| Symptoms present | |||
| No (n=1009) | 64 (6.34) | 1 | |
| Yes (n=3461) | 374 (10.9) | 1.81 (1.38 to 2.39)* | |
| Previous gonorrhoea infection | |||
| No (n=1736) | 195 (11.2) | 1 | |
| Yes (n=2712) | 236 (8.70) | 0.75 (0.62 to 0.92)* | |
| Concurrent chlamydia infection | |||
| No (n=2713) | 349 (12.9) | 1 | 1 |
| Yes (n=1615) | 58 (3.59) | 0.25 (0.19 to 0.34)* | 0.58 (0.50 to 0.68)* |
| HIV status | |||
| Negative (n=3345) | 326 (9.75) | 1 | |
| Positive (n=36) | 10 (27.8) | 3.56 (1.70 to 7.46)* | |
| Year | |||
| 2007 (n=664) | 43 (6.48) | 1 | 1 |
| 2008 (n=745) | 41 (5.50) | 0.84 (0.54 to 1.31) | 0.60 (0.45 to 0.80)* |
| 2009 (n=797) | 101 (12.7) | 2.09 (1.44 to 3.05)* | 1.89 (1.50 to 2.39)* |
| 2010 (n=616) | 54 (8.77) | 1.39 (0.91 to 2.10) | 1.85 (1.46 to 2.39)* |
| 2011 (n=593) | 56 (9.44) | 1.51 (0.99 to 2.28) | 1.42 (1.12 to 1.81)* |
| 2012 (n=585) | 59 (10.1) | 1.62 (1.07 to 2.44)* | 1.01 (0.77 to 1.33) |
| 2013 (n=626) | 104 (16.6) | 2.88 (1.97 to 4.20)* | 1.22 (0.96 to 1.55) |
| Gender | |||
| Men (n=2732) | 323 (11.8) | 1 | 1 |
| Women (n=1894) | 135 (7.13) | 0.57 (0.46 to 0.71)* | 0.42 (0.34 to 0.52)* |
| Isolation site | |||
| Genital (n=4462) | 416 (9.30) | 1 | 1 |
| Rectal (n=73) | 18 (24.7) | 3.18 (1.85 to 5.48)* | 1.69 (1.46 to 1.96)* |
| Throat (n=57) | 20 (34.1) | 5.26 (3.01 to 9.17)* | 1.84 (1.44 to 2.34)* |
| Other (n=34) | 4 (11.8) | 1.30 (0.45 to 3.70) | 1.12 (0.51 to 2.48) |
*p<0.05.
MIC, minimum inhibitory concentration.